Skip to content
Review Open access

Engineered Nanozymes for Colorectal Cancer Therapy: Catalytic Reprogramming of the Tumor Microenvironment

Aug 2026 · International Journal of Nanomedicine · Vol 21, pp. 1-33 · 0 citations · 173 references
Medicine

TL;DR

This review critically compares metal, metal-oxide, carbon-based, porous-framework, and single-atom nanozymes with respect to catalytic mechanism, enzyme-mimicking activity, substrate dependence, controllability, biosafety, and translational suitability and position CRC nanozyme therapy as a disease-oriented catalytic medicine platform whose clinical value will depend on biomarker-guided selection, programmable activation, and degradable, locally controllable designs.

Abstract

Abstract Colorectal cancer (CRC) remains difficult to treat because redox adaptation, metabolic plasticity, mucin-associated delivery barriers, immune exclusion, and microbiota-dependent signaling jointly limit conventional therapy. Engineered nanozymes provide a reaction-centered strategy for exploiting these CRC-specific vulnerabilities. This review critically compares metal, metal-oxide, carbon-based, porous-framework, and single-atom nanozymes with respect to catalytic mechanism, enzyme-mimicking activity, substrate dependence, controllability, biosafety, and translational suitability. We examine how acidity, hydrogen peroxide, hypoxia, glutathione enrichment, metabolic dysregulation, mucin barriers, and the gut microbiota influence catalytic performance. We further evaluate evidence for chemotherapy sensitization, chemodynamic, photothermal, photodynamic, sonodynamic, immunotherapeutic, and multimodal treatment, emphasizing both mechanistic synergy and limitations of the available preclinical models. Major translational barriers include non-standardized catalytic assays, heterogeneous intratumoral substrates, off-target reactive oxygen species toxicity, uncertain degradation and long-term fate, microbiome disruption, manufacturing reproducibility, and limited validation in orthotopic, immunocompetent, organoid, and patient-derived systems. We therefore position CRC nanozyme therapy as a disease-oriented catalytic medicine platform whose clinical value will depend on biomarker-guided selection, programmable activation, and degradable, locally controllable designs.

Read PDF

Similar papers

Review Open access Aug 2026

Stimuli-responsive bioengineered platforms for precision cancer therapy

The evidence supports a conceptual transition from passive nanocarriers to programmable therapeutic systems capable of aligning therapeutic action with the spatial, temporal, and biological heterogeneity of tumors, but translation remains constrained by formulation complexity, incomplete standardization, limited long-t...

Hamid Omidian, Renae L. Wilson · 1 citation
Review Open access Aug 2026

Piezoelectric nanozymes: a new frontier for next-generation tumor therapeutics

Piezoelectric nanozymes offer a versatile platform for multimodal cancer therapy and represent a promising paradigm for developing strategies for precise, non-invasive cancer therapy through localized ROS generation and modulation of the TME.

Akanksha Deshwal, A. Vimal, Prachi Nirwan et al. · 0 citations
Review Open access Sep 2026

Nanozymes in Tumor Microenvironment Modulation for Cancer Therapy

This review systematically summarizes recent advances in nanozyme-mediated regulation of the TME and aims to provide a theoretical basis and research perspectives for the further study, rational design, and translational application of nanozymes in cancer therapy.

Xin-Yang Zhang, Zi-Qi Wang, Yang Niu et al. · 0 citations
Review Open access Sep 2026

Research Advances in Nanodrugs Targeting Lipid Metabolism Reprogramming for Colorectal Cancer Therapy

Abstract Colorectal cancer (CRC) remains a major global health burden, with limited efficacy of conventional treatments due to tumor heterogeneity, drug resistance, and systemic toxicity. Lipid metabolism reprogramming has emerged as a hallmark of CRC progression, influencing tumor growth, metastasis, and therapy resis...

Jing-Wen Tang, Meng-Nan Liu, Rui-Zhi Zhang et al. · 0 citations
Review Sep 2026

Reprogramming the Tumor Microenvironment and Cancer Therapy via Nanocatalytic Medicine

Cancer is one of the leading global health crises in the 21st century, accounting for nearly one in six deaths worldwide. Conventional treatment modalities, including surgery, chemotherapy, radiotherapy, and immunotherapy, remain insufficient and are frequently sabotaged due to the tumor complexity. Parallelly, there...

Rahul Bhardwaj, Anjali Nisha, Harpreet Kaur et al. · 0 citations
Review Sep 2026

Engineered nano-delivery platforms targeting ferroptosis-evasion pathways to reverse tumor drug resistance.

Tumor multidrug resistance remains a major driver of treatment failure, largely due to the adaptive plasticity that enables cancer cells to evade conventional therapies. Ferroptosis, a non-apoptotic cell-death modality driven by iron-dependent lipid peroxidation, offers a mechanistically distinct route to overcome ther...

Kun-Teng Yang, Xiang-Ling Ren, Qiong Wu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.